Substituted piperidinylcarbonylbenzenesulfonamides as calcium channel blockers

1. A compound of formula (I) or formula (II),

or a pharmaceutically acceptable salt thereof, wherein

R 1 is X, and R 2 is Y;

X is (ii);

G 1 is azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or azepanyl, wherein G 1 is connected through the nitrogen atom of said azetidinyl, pyrrolidinyl, piperidinyl, morpholinyl, thiomorpholinyl or azepanyl;

Y is —NR c Ar 1 , —NR c Ar 2 —Ar 1 , —NR c CH(Ar 1 ) 2 , —NR c (CR a R b ) p CH(Ar 1 ) 2 , —NR c (CR a R b ) p CH(Ar 1 ) 2 , —NR c —G 2 , —NR c —G 2 —Ar 1 , (iii), (iv), (v) or (vi);

Ar 1 , at each occurrence, is independently aryl or heteroaryl, wherein said aryl and heteroaryl are unsubstituted or substituted with 1, 2, 3, 4, or 5 substituents selected from alkoxy, alkyl, cyano, haloalkyl, halogen, or —N(alkyl) 2 ;

Ar 2 is aryl or heteroaryl, wherein said aryl and heteroaryl are unsubstituted or substituted with 1, 2, 3, or 4 substituents selected from alkoxy, alkyl, cyano, haloalkyl, or halogen;

G 2 is cycloalkyl;

R a and R b are at each occurrence independently hydrogen, alkyl, or hydroxyalkyl;

R c is hydrogen or alkyl;

p is 1, 2, 3, or 4; and

R 3 , R 4 , R 5 and R 6 are each independently hydrogen, alkoxy, alkyl, or halogen.

2. The compound according to claim 1 of formula (I), or a pharmaceutically acceptable salt thereof.

3. The compound according to claim 2 of formula (I), or a pharmaceutically acceptable salt thereof, wherein

G 1 is pyrrolidinyl or piperidinyl;

R 2 is Y;

Y is NR c Ar 1 ;

R c is hydrogen; and

Ar 1 is aryl, wherein said aryl is unsubstituted or substituted with 1, 2, or 3 substituents selected from haloalkyl and halogen.

4. The compound according to claim 1 , or a pharmaceutically acceptable salt thereof, wherein the compound is selected from the group consisting of:

N-(4-fluorophenyl)-3-[(4-pyrrolidin-1-ylpiperidin-1-yl)carbonyl]benzenesulfonamide;

N-phenyl-3-[(4-pyrrolidin-l-ylpiperidin-l-yl)carbonyl]benzenesulfonamide;

3-[(4-pyrrolidin-l-ylpiperidin-l-yl)carbonyl]-N- [4-(trifluoromethyl)phenyl]benzenesulfonamide;

3-[(4-pyrrolidin-l-ylpiperidin-l-yl)carbonyl]-N- [3-(trifluoromethyl)phenyl]benzenesulfonamide;

N-(3-fluorophenyl)-3-[(4-pyrrolidin-1-ylpiperidin-1-yl)carbonyl]benzenesulfonamide;

N-(2-fluorophenyl)-3-[(4-pyrrolidin-1-ylpiperidin-1-yl)carbonyl]benzenesulfonamide;

3-(1,4′-bipiperidin-l′-ylcarbonyl)-N-(4-fluorophenyl)benzenesulfonamide;

3-(1,4′-bipiperidin-l′-ylcarbonyl)-N-(2-fluorophenyl)benzenesulfonamide;

3-(1,4′-bipiperidin-l′-ylcarbonyl)-N-(3-fluorophenyl)benzenesulfonamide; and

3-(1,4′-bipiperidin-l′-ylcarbonyl)-N-[4-(trifluoromethyl)phenyl]benzenesulfonamide

5. A pharmaceutical composition comprising a therapeutically effective amount of a compound of formula (I) or formula (II) according to claim 1 , or a pharmaceutically acceptable salt thereof, in combination with a pharmaceutically acceptable carrier.